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Using CD4 Percentage and Age to Optimize Pediatric
Antiretroviral Therapy Initiation
WHAT’S KNOWN ON THIS SUBJECT: In HIV-infected children,
decisions to start antiretroviral therapy must weigh immunologic
benefits against potential risks. Current guidelines recommend
using CD4 percentage and age when deciding to start treatment.
Population-level effects of these factors on immunologic recovery
are unknown.
WHAT THIS STUDY ADDS: Starting antiretroviral therapy at higher
CD4 percentages and younger ages maximizes potential for
immunologic recovery. However, not all benefits are sustained,
and viral failure may occur. Our results help clinicians better
weigh immunologic benefits against viral failure risks.
abstract
BACKGROUND: Quantifying pediatric immunologic recovery by highly
active antiretroviral therapy (HAART) initiation at different CD4 percent-
age (CD4%) and age thresholds may inform decisions about timing of
treatment initiation.
METHODS: HIV-1-infected, HAART-naive children in Europe and the Americas
were followed from 2002 through 2009 in PENPACT-1. Data from 162 ver-
tically infected children, with at least World Health Organization “mild”
immunosuppression and CD4% ,10th percentile, were analyzed for
improvement to a normal CD4% ($10th percentile) within 4 years after
HAART initiation. Data from 209 vertically infected children, regardless
of immune status, were analyzed for CD4% outcomes at 4 years and
viral failure within 4 years.
RESULTS: Seventy-two percent of baseline immunosuppressed children
recovered to normal within 4 years. Compared with “severe” immuno-
suppression, more children with “mild” immunosuppression (differ-
ence 36%, 95% confidence interval [CI]: 22% to 49%) or “advanced”
immunosuppression (difference 20.8%, 95% CI: 5.8% to 35.9%) recov-
ered a normal CD4%. For each 5-year increase in baseline age, the
proportion of children achieving a normal CD4% declined by 19% (95%
CI: 11% to 27%). Combining baseline CD4% and age effects resulted in
.90% recovery when initiating HAART with “mild” immunosuppression
at any age or “advanced” immunosuppression at age ,3 years. Base-
line CD4% effects became greater with increasing age (P = .02). At 4
years, most immunologic benefits were still significant but diminished.
Viral failure was highest in infancy (56%) and adolescence (63%).
CONCLUSIONS: Initiating HAART at higher CD4% and younger ages max-
imizes potential for immunologic recovery. Guidelines should weigh immu-
nologic benefits against long-term risks. Pediatrics 2014;134:e1104–e1116
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Determining optimal timing for initiation
of highly active antiretroviral therapy
(HAART) in children infected with HIV
remains a challenge. Globally in 2012,
3.3 million children were living with HIV,
and 210 000 children died due to AIDS.1
Although HAART has improved long-term
survival,2 only 34% of eligible children
currently receive treatment.1 Treatment
guidelines must consider public health
implications for not only disease pro-
gression,2,3 but also long-term compli-
cations of drug toxicities,4 inadequate
adherence,5–7 resistance mutations,5 and
cost-effectiveness. For HIV-infected infants,
immediate HAART initiation is clearly
needed, given its strong survival benefit,8,9
improved neurodevelopmental out-
comes,10 faster growth recovery,11 and
the population’s high mortality.12,13 How-
ever, for HIV-infected children presenting
outside of infancy with minimal HIV-
related symptoms, the clinical benefits
of early HAART initiation are unclear.14,15
Quantifying immunologic benefits of
treatment initiation at different CD4
percentage (CD4%) and age thresholds
may inform public health decisions re-
garding optimal HAART initiation timing.
Population-level immunologic effects of
HAART initiation at different CD4% and
age combinations have been poorly
quantified because most previous stud-
ies have only assessed associations.
HIV-infectedchildrenwho initiateHAART
at lower CD4% reach lower peak CD4
levels,4,16–24 perhaps from persistent
effects of chronic immune activation.25,26
HAART initiation at younger ages is as-
sociated with better immunologic re-
covery.17–20,24,27,28 Some longitudinal
studies have quantified long-term CD4
trajectories on HAART based on pre-
treatment CD4 and age, allowing pre-
dictions that are child-specific.24,29
However, projected immunologic im-
pacts at population levels have not been
established.
Our aim was to quantify population-
level impacts of HAART initiation at
different CD4% and age thresholds on
CD4% recovery. Our primary outcome
was the proportion of immunosup-
pressed children ever achieving a nor-
mal CD4% ($10th percentile for age30)
within 4 years of HAART initiation. Sec-
ondary outcomeswere CD4% at 4 years
after HAART initiation and the pro-
portion of children with a normal CD4%
at 4 years. The proportion of immuno-
suppressed children ever having a
normal CD4% within 4 years of HAART
initiation reflects biological capacity
for CD4% reconstitution. The CD4% and
proportion of children normal at 4 years
reflect outcomes inclusive of initial
CD4% recovery, potential immunologic
failure, and possible immune resto-
ration on a subsequent regimen.
METHODS
Participants
PENPACT-1 (Pediatric AIDS Clinical Trials
Group 390/Paediatric European Network
for Treatment of AIDS 9)31 was an in-
ternational, multicenter, phase 2/3, ran-
domized, open-label, 2-by-2 factorial trial
enrolling HIV-1–infected children (aged
.30 days to ,18 years) in Europe,
North America, and South America be-
tween September 25, 2002, and Sep-
tember 7, 2005. Eligible children had not
been treated with antiretrovirals or only
received antiretrovirals to reduce mother-
to-child transmission (excluding single-
dose nevirapine) for,56 days and met
local indications for HAART.
Procedures
At entry, children were randomly
assigned (1:1) in 2-by-2 factorial design:
(1) to start HAART with 2 nucleoside re-
verse transcriptase inhibitorsplus either
a protease inhibitor or nonnucleoside
reverse transcriptase inhibitorand (2) to
switch from first-line to second-line
HAART at viral load thresholds of either
1000 copies/mL or 30 000 copies/mL.
CD4% and HIV RNA viral loads were
measured at randomization (baseline,
week 0); weeks 2, 4, 8, 12, 16, 24; and
then every 12 weeks until the last
enrollee reached 4 years of follow-up
(August 31, 2009). Full study details are
described elsewhere.31
Because previous PENPACT-1 analyses
found no significant differences among
randomizedarms,31wepooledparticipants
across arms. To minimize confounding
from unknown duration of infection,
analyseswere restricted to participants
who were infected vertically.
For the primary outcome (CD4% re-
covery within 4 years), data from ver-
tically infected children with at least
“mild” immunosuppression at baseline
by World Health Organization (WHO)
Immunologic Classification32 and CD4%
,10th percentile for age30 were ana-
lyzed to determine the proportion of
children who improved to normal
CD4% ($10th percentile for age30) at
any timewithin 4 years of follow-up. For
secondary outcomes, data from all
vertically infected children, regardless
of baseline immune status, were ana-
lyzed for outcomes at 4 years after
HAART initiation: CD4% and proportion
of children with normal CD4% (see
definitions in the next section).
Definitions
To account for age-related variability
of CD4%, we defined normal CD4% re-
covery based on data from healthy,
urban-dwelling, pediatric patients in
the United States.30 For the primary
outcome, recovery to normal was de-
fined as 2 consecutive CD4% mea-
surements $10th percentile-for-age.
Time of recovery was defined as the
first of these CD4% measurements.
Participants lost to follow-up without
recovery were censored in Kaplan-Meier
analyses and counted as failures in re-
gression analyses.
For secondary outcomes, CD4% at 4
yearswas defined as themean of CD4%
measurements at weeks 192 and 204.
At week 192, all participants were $3
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years old, and CD4% 10th percentile-
for-age after 3 years old ranges be-
tween 28% to 31% without a consistent
age-related trend. Thus, the definition
of normal CD4% at 4 years was sim-
plified to be mean CD4% $30%.30,33
Participants missing 4-year CD4% mea-
surements were excluded from second-
ary outcome analyses.
BaselineCD4%wascategorizedaccording
to a modified version of the WHO Immu-
nologic Classification for HIV-Associated
Immunodeficiency.32 As this classification
switches to CD4 cell counts after age 5
years, we used the following immunode-
ficiency (CD4%) categories for subjects
$5 years (same as ages 3 to ,5 years;
see also the Centers for Disease Control
and Prevention [CDC] HIV infection clas-
sification systems34,35): “none/not sig-
nificant” .25%, “mild” 20% to 25%,
“advanced” 15 to ,20%, and “severe”
,15%.
Statistical Analysis
Bivariate categorical analyses were
performed by using Fisher’s exact test.
Continuous variables were analyzed
by using linear regression. Trend line-
arity was assessed by using polynomial
expansion and restricted quadratic
splines with knots between quintiles.
Recovery to normal CD4%within 4 years
was analyzed by Kaplan-Meier methods
with log-rank statistics and modified
Poisson regression on an additive scale
with Huber-White variance estimators
(additive Poisson).36,37 CD4% at 4 years
was analyzed by using multivariable
linear regression while having normal
CD4% at 4 years used additive Poisson
regression. Models were constructed
by using published literature and
hypothesis-driven a priori assumptions
to guide statistical assumptions,38,39
then reduced by backward elimination
using P , .15 and .10% change-in-
estimate criteria. Models estimating
baseline CD4% main effects were ad-
justed for age, gender, and race. Models
estimating age main effects were ad-
justed for gender and race. Interactions
between immunologic classification and
age were assessed and retained in
models if P , .15. Hypothesis tests in
Poisson regression used score statistics;
linear regression used likelihood ratio
tests. Statistical significancewas defined
as 2-sided P, .05.
Models were not adjusted for adher-
ence or viral failure because both vari-
ables are on the causal pathway to
CD4% recovery.38 Adjustment for ad-
herence or viral failure would control
for information unavailable to clinicians
when making decisions about treat-
ment initiation and would add bias to
estimates.40 However, we evaluated viral
failure to assess the degree to which
immunologic outcomes may be explained
by poor viral control. Viral failure was
defined as (1) failure to suppress HIV
RNAviral load to#400 copies/mLbyweek
24 of HAART or (2) after initial viral sup-
pression, viral load .400 copies/mL for
2 consecutive measurements, the first
occurring by week 192. Analyses used
Cox models for testing associations
and stratified proportional hazards
models41 to estimate adjusted Kaplan-
Meier failure probabilities. CD4% main
effect estimates were adjusted for age,
continent, and baseline viral load. Age
main effect estimates were adjusted for
continent.
Alosstofollow-up(LTFU)analysisevaluated
bivariate relationships between baseline
characteristics and missing CD4% values
at4years.Toassessthepotential influence
of LTFU on results, sensitivity analyses
corrected CD4% outcomes at 4 years for
LTFU by using a method similar to direct
standardization (inverse-probability
weighting methods).42
Statistical analyses used SAS ver-
sion 9.3 (Cary, NC). This study is reg-
istered with International Standard
Randomised Controlled Trial Number Reg-
ister (ISRCTN73318385). The study pro-
tocol was deemed exempt by institutional
review boards at Duke University and





with HIV-1 from 68 centers in 13 coun-
tries in Europe, North America, and
South America; 263 were included in the
main trial analysis. For analysis of
CD4% recovery within 4 years, 162 par-
ticipants with baseline immunosuppres-
sion were included, and 209 qualified
for analyses of CD4% status at 4 years
(Supplemental Fig 4). The baseline char-
acteristics of all 209 vertically infected
participants are shown in Table 1. At
baseline, WHO-staged CD4% was
associated with age, race, and gender;
marginally associated with continent
andCDC clinical stage; and not associated
with growth parameters (weight-for-
age z score, height-for-age z score, and
BMI-for-age z score) or baseline viral load.
Age at HAART initiation was associated
with race, continent, growth parameters,
baseline viral load, and baseline CD4%
but not associated with gender or CDC
clinical stage.
Eighty-seven percent (182 of 209) of
participants had follow-up CD4% mea-
surements at 4 years. LTFU was only
associated with continent (Europe 5%,
North America 27%, South America 10%;
P , .001). Correcting for LTFU did not
meaningfully alter study results (data
not shown).
Of 162 children with baseline immu-
nosuppression, the estimated proba-
bility of achievinganormal CD4%within
4 years was 72% (95% confidence in-
terval [CI]: 64% to 78%);meanCD4%at 4
yearswas30.9 (95%CI: 29.5 to32.3); 56%
ofparticipants (95%CI: 48% to64%)had
normal CD4%at 4 years. Of 209 children
with any baseline immune status,mean
CD4%at 4 yearswas32.8 (95%CI: 31.5 to
34.2), with 64% (95% CI: 57% to 71%) of
childrenhavingnormalCD4%at4years.
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Baseline CD4%
CD4% recovery within 4 years was signif-
icantly associated with WHO-staged base-
line CD4% (Kaplan-Meier, P, .001; Fig 1).
In regression models, baseline CD4% was
significantly associated with all three
4-year CD4% outcomes: proportion of
immune suppressed children ever re-
covering a normal CD4% within 4 years
(unadjusted P, .001, adjusted P, .001;
Fig 1); CD4% at 4 years (unadjusted P ,
.001, adjusted P , .001; Table 2); and
proportion of children normal at 4 years
(unadjusted P, .001, adjusted P, .001;
Table 2). Compared with WHO “severe”
immunosuppression, each increase in
baselineCD4%categoryhadan increasing
trend in proportion of children ever nor-
mal within 4 years (Fig 1), CD4%at 4 years
(Table 2), and proportion of children nor-
mal at 4 years (Table 2).
Age at HAART Initiation
CD4% recovery within 4 years was sig-
nificantly associated with age (Kaplan-
Meier, P , .001; Fig 2). The association
between age and CD4% recovery was
approximately linear (by significance
testing) for all three 4-year CD4% out-
comes (Fig 3A–3C). In multivariable lin-
ear regressions adjusting for gender
and race, each 5-year increase in age at
HAART initiation had an estimated (1)
reduction of 19% in proportion of chil-
dren ever having a normal CD4% within
4 years (95% CI: 11% to 27%; P, .001),
(2) decrease in CD4% at 4 years of 2.9
percentage points (95% CI: 1.4% to 4.3%;
P , .001), and (3) reduction in pro-
portion of children with a normal
CD4% at 4 years of 7% (95% CI: –1% to
16%; P = .08).
Combined Effects of Baseline CD4%
and Age
The interaction between baseline CD4%
and age on the probability of ever re-
covering a normal CD4% within 4 years
was statistically significant (unadjusted
P = .009, adjusted P = .02; Table 3). This
interactionwassynergistic:with increasing
age, baseline CD4% had a stronger ef-
fect on the capacity to recover a normal
CD4%within 4 years. However, interactions
TABLE 1 Characteristics of Children According to WHO Staged CD4% and Age at HAART Initiation
Variable WHO Immunologic Classification for HIV-Associated Immunodeficiency
at HAART Initiation
Age (y) at HAART
Initiation
Severe Advanced Mild None Total Pa Mean (SD) P
n 91 40 34 44 209
Age, n (%)
0–4 y 41 (41) 13 (13) 18 (18) 27 (27) 99 .07 2.0 (1.5) N/A
5–9 y 27 (39) 18 (26) 12 (17) 13 (19) 70 8.0 (2.2)
10–17 y 23 (58) 9 (23) 4 (10) 4 (10) 40 15.1 (1.5)
Age, y, M (SD) 6.3 (4.7) 7.0 (4.7) 4.9 (4.0) 4.2 (3.8) 5.8 (4.5) .01 5.8 (4.5)
Gender
Female, n (%) 35 (34) 18 (17) 25 (24) 25 (24) 103 .003 5.6 (4.5) .59
Male 56 (53) 22 (21) 9 (8) 19 (18) 106 6.0 (4.6)
Race, n (%)
Black, non-Hispanic 48 (42) 26 (23) 22 (19) 18 (16) 114 .04 6.8 (4.8) ,.001
White, non-Hispanic 12 (34) 5 (14) 3 (9) 15 (43) 35 3.2 (3.3)
Hispanic/other 31 (52) 9 (15) 9 (15) 11 (18) 60 5.5 (4.0)
Continent, n (%)
Europe 40 (43) 26 (28) 13 (14) 15 (16) 94 .05 5.0 (3.9) .002
North America 30 (48) 10 (16) 9 (14) 14 (22) 63 7.4 (5.5)
South America 21 (40) 4 (8) 12 (23) 15 (29) 52 5.2 (3.6)
CDC clinical stage, n (%)
N or A 41 (37) 24 (22) 24 (22) 22 (20) 111 .06 5.9 (4.8) .78
B or C 50 (51) 16 (16) 10 (10) 22 (22) 98 5.7 (4.1)
Treatment regimen, n (%)
NNRTI 46 (43) 16 (15) 22 (21) 22 (21) 106 N/Ab 5.3 (4.1) N/Ab
PI 45 (44) 24 (23) 12 (12) 22 (21) 103 6.3 (4.9)
Switching threshold, n (%)
1000 copies/mL 46 (44) 19 (18) 14 (13) 25 (24) 104 N/Ab 5.6 (4.5) N/Ab
30 000 copies/mL 45 (43) 21 (20) 20 (19) 19 (18) 105 6.0 (4.5)
z score, M (SD)
Weight for age 20.6 (1.6) 20.8 (1.2) 20.6 (1.1) 20.7 (1.5) 20.7 (1.4) .81 r = 0.32 ,.001
Height for age 21.0 (1.4) 21.0 (0.8) 20.8 (1.1) 20.8 (1.3) 20.9 (1.2) .81 r = 0.16 .02
BMI 20.0 (1.4) 20.4 (1.5) 20.2 (1.2) 20.2 (1.3) 20.2 (1.4) .59 r = 0.29 ,.001
Baseline viral load log10 copies/mL, M (SD) 5.2 (0.9) 5.1 (0.8) 4.8 (1.0) 5.0 (0.8) 5.1 (0.9) .31 r = –0.54 ,.001
Baseline CD4%, M (SD) 10.2 (5.7) 18.5 (3.8) 25.4 (4.9) 35.6 (7.1) 19.6 (11.4) N/A r = –0.44 ,.001
N/A, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Comparisons used Fisher’s exact test for categorical variables and linear regression for continuous variables.
b P values are not reported because any differences were determined by randomization.
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between baseline CD4% and age were
not significant for CD4% at 4 years (un-
adjusted P = .91; adjusted P = .91) or the
proportion of children with normal CD4%
at 4 years (unadjusted P = .50, adjusted
P = .59; Table 4).
A model including baseline CD4%, age,
gender, race, and a baseline CD4%-by-
age interaction predicted .90% prob-
ability of CD4% recovery within 4 years
when initiating HAART with “mild” im-
munosuppression at any age or with
“advanced” immunosuppression at
age ,3 years. Adolescents with WHO
“severe” immunosuppression had the
lowest recovery probabilities, but the
small sample size of adolescents made
these estimates imprecise (Table 3).
Trends were similar for CD4% out-
comes at 4 years (Table 4).
Viral Failure
Of 209 vertically infected participants,
82 (39%) experienced viral failure within
4 years. Twenty-nine (14%) failed to sup-
press to#400 copies/mL byweek 24, and
53 (25%) suppressed but experienced vi-
ral rebound to .400 copies/mL. One
participant (0.5%) was LTFU before week
24. Viral failure was not associated
(Cox model, unadjusted P = .36, adjusted
P = .23) with baseline immunodeficiency
classification (adjusted Kaplan-Meier fail-
ure probability: “none” 32%, “mild” 54%,
“advanced” 44%, “severe” 40%). Viral
failure and age had a bimodal relation-
ship (Cox model, unadjusted P , .001,
adjusted P, .001) with peaks in infancy
and adolescence (adjusted Kaplan-Meier
failure probability: 0 to,1 year 56%, 1 to
,3 years 34%, 3 to ,5 years 32%, 5 to
,8 years 24%, 8 to ,13 years 38%, 13
to, 18 years 63%; Fig 3D).
DISCUSSION
On the basis of these PENPACT-1 results,
initiatingHAARTat healthier immunologic
stages and younger ages may have pro-
found impacts on immunologic recovery.
We suggest that HAART initiation when
children first have “mild” immunosup-
pression would result in almost all chil-
dren experiencing full CD4% recovery.
Similarly, HAART at younger ages would
yield high probabilities of immune re-
covery and may blunt negative effects of
“severe” immunosuppression. Although
not all children maintained immune re-
covery (demonstrated bymore attenuated
immunologic benefits at 4 years) most
CD4% outcomes at 4 years were still im-
proved in children starting HAART at
healthier CD4 levels andyoungerages. Our
results quantify the magnitude of these
effects on immunologic outcomes to help
inform public health planning.
The PENPACT-1 data align with US De-
partment of Health and Human Services
(DHHS) pediatric HIV treatment guide-
lines.3,43 The DHHS recommends initiating
HAART in all HIV-infected infants and
any HIV-infected children with AIDS or
most CDC Clinical Category B or C con-
ditions; confirmed plasma HIV RNA levels
FIGURE 1
Cumulative proportion of childrenwith CD4% recovery to normal versusweeks after HAART initiation, by
baseline WHO Immunodeficiency Classification (“mild,” “advanced,” “severe”). Primary outcome is
CD4%$10th percentile for age by week 192, marked by vertical dashed line. P value is from log-rank
statistic.
e1108 YIN et al
.100 000 copies/mL; aged 1 to,3 years
with CD4 cell count,1000 cells/mm3 or
CD4%,25%; ages 3 to,5 yearswith CD4
count ,750 cells/mm3 or ,25%; or age
$5 yearswith CD4 count,500 cells/mm3
(with considerations for treating at
higher CD4 levels).43 DHHS-recommended
CD4% and age treatment thresholds
correspond to WHO immunodeficiency
classifications of “advanced” for ages
1 to ,3 years and “mild” for all age
categories$3 years. If all children aged
1 to ,13 years in PENPACT-1 had initi-
ated HAART immediately after reaching
DHHS-recommended CD4% and age treat-
ment thresholds, we estimate.90% of
these children would have experienced
CD4% recovery to normalwithin 4 years,
and .80% would have had a normal
CD4% at 4 years.
Evidence supporting early treatment is
strongest in infants. A randomized con-
trolled trial (RCT) of HIV-infected infants
in South Africa found that, compared
with delaying treatment until infants met
prespecified clinical or CD4% criteria,
immediateHAART initiationreducedearly
infant mortality by 76% and HIV pro-
gression by 75%.8 Infantswith immediate
treatment had better gross motor and
general neurodevelopmental scores,10
and treatment ,6 months old may
have faster improvements in weight-for-
age and head circumference-for-age
z scores.11 A Cochrane review on
effectiveness of HAART in HIV-infected
children ,3 years old concluded that
immediate HAART reduces morbidity
and mortality in infants, but clinical
benefits of universal treatment initia-
tion in children aged 1 to 3 years remain
unclear.9
Evidence for early treatment in children
$1 year old is less compelling. An
RCT in Thailand and Cambodia of HIV-
infected children aged 1 to 12 years
with CD4% 15% to 24% found that im-
mediate versus delayed HAART resulted
in similar 144-week AIDS-free survival
(98.7% vs 97.9%) but improved height
z scores and higher CD4% (33.2% vs
24.8%).15 Neurodevelopmental scores
were no different across arms.14 Links
among pretreatment CD4, age, and
long-term CD4 recovery have been
established in literature.17–20,24 How-
ever, our estimates allow the reader
to quantify population-level immuno-
logic benefits of early versus delayed
treatment at combinations of CD4%
and age.
Adolescent recommendations are based
primarily on adult data.44 Adult RCTs
found decreased AIDS progression or
death with HAART in patients with acute
opportunistic illnesses,45 CD4,200 cells/
mm3,46 or CD4 200 to ,350 cells/mm3.47
Adult cohort studies suggest that initi-
ating HAART at CD4 counts 350 to 500
cells/mm3 reduces HIV-related disease
progression but have conflicting results
at CD4 .500 cells/mm3.48–51 Adult data
further support earlier treatment to
enhance CD4 recovery52 and prevent
HIV sexual transmission.53 Consequently,
DHHS guidelines recommend universal
HAART in all HIV-infected adults and
adolescents.44
From our PENPACT-1 results, we are
concerned by the poor outcomes in
older children and adolescents, partic-
ularly those with poor baseline immu-
nologic status. Biologically, we expected
relationships between CD4% recovery
and age to plateau because thymic po-
tential stabilizes as children approach
adult immune maturity.24,27,28 Instead,
CD4% outcomes declined through ado-
lescence, likely from increasing ad-
herence struggles and viral failure.7,54
Consistent with child-specific pre-
dictions,24 older children and adoles-
cents may benefit most dramatically
from earlier HAART initiation (comple-
mentary to strategies for better case
finding, adherence, or therapeutic
approaches for improving immuno-
logic potential).
Immunologic benefits of earlier treatment
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harms. In PENPACT-1, viral failure was
worse at age extremes, consistent with
studies finding poor viral suppression
at younger ages6,19 and myriad adher-
ence difficulties in adolescents.7,54 For
some children, immunologic recovery
is transient, and starting HAART earlier
may eventually lead to fewer treatment
options. Fortunately, HAART initiation at
higher CD4 counts may mitigate anti-
retroviral resistance at viral failure.55
Still, diminishing immunologic benefits
over time and viral failure risks high-
light the importance of long-term lon-
gitudinal studies for understanding
implications of different HAART strate-
gies in children.
Our study was limited by including only
participants from a clinical trial in
predominantly industrialized countries.
Results may not generalize to other set-
tings. Low sample sizes in certain CD4%
and age strata, particularly adolescents,
decreased precision of estimates and
precluded more intricate model speci-
fication. Finally, analysis of potential
sources of bias38 suggested possible
unmeasured confounding from host
immunology and HIV virulence, which
were untestable in our data.
CONCLUSIONS
Earlier HAART initiation in children with
vertically acquired HIV-1 substantially
improves immunologic recovery within
4 years. Optimizing treatment timing
by CD4% and age may have significant
long-term immunologic benefits. Older
children and adolescents, in particular,
may benefit from earlier treatment.
Nevertheless, immunologic benefits
diminished over time, and treatment
decisions should weigh potential
risks, including viral failure. Esti-
mates of this kind allow immunologic
benefits of alternative HAART initia-
tion thresholds to be balanced against
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FIGURE 2
Cumulative proportion of childrenwith CD4% recovery to normal versusweeks after HAART initiation, by
age at HAART initiation (0–4, 5–9, 10–17 years). Primary outcome is CD4%$10th percentile for age by
week 192, marked by vertical dashed line. P value is from log-rank statistic.
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Data and Safety Monitoring Board:
B. Brody, C. Hill, P. Lepage, J. Modlin,
A. Poziak, M. Rein (Chair 2002–2003),
M. Robb (Chair 2004–2009), T. Fleming,
S. Vella, K.M. Kim.
Clinical Sites (L = laboratory,
P = pharmacy)
Argentina: Hospital de Pediatria Dr
J.P. Garrahan, Buenos Aires: R. Bologna,
D. Mecikovsky, N. Pineda, L. Sen (L),
A.Mangano (L), S.Marino (L), C.Galvez (L);
Laboratorio Fundai: G. Deluchi (L).
Austria: Universitätsklinik für Kinder
und Jugendheilkunde, Graz: B. Zöhrer,
W. Zenz, E. Daghofer, K. Pfurtscheller,
B. Pabst (L).
Bahamas: Princess Margaret Hospital:
M.P. Gomez, P.McNeil,M. Jervis, I. Whyms,
D. Kwolfe, S. Scott (P).
Brazil: University of São Paulo at
Ribeirão Preto: M.M. Mussi-Pinhata,
M.L. Issac, M.C. Cervi, B.V.M. Negrini,
T.C. Matsubara, C.B.S.S. de Souza (L),
J.C. Gabaldi (P); Institute of Pediatrics
(IPPMG), Federal University of Rio de
Janeiro: R.H. Oliveira, M.C. Sapia, T. Abreu,
L. Evangelista, A. Pala, I. Fernandes,
I. Farias, M. de F. Melo (L), H. Carreira (P),
L.M. Lira (P); Instituto de Infectologia
Emilio Ribas, São Paolo: M. Della Negra,
W. Queiroz, Y.C. Lian; D.P. Pacola; Fleury
Laboratories; Federal University of Minas
Gerais, Belo Horizonte: J. Pinto, F. Ferreira,
F. Kakehasi, L. Martins, A. Diniz, V. Lobato,
M. Diniz, C. Hill (L), S. Cleto (L), S. Costa (P),
J. Romeiro (P).
France: Hôpital d’enfants Armand
Trousseau, Paris: C. Dollfus, M.D. Tabone,
FIGURE 3
RelationshipbetweenageatHAART initiationand(A)proportionof childrenwithnormalCD4%within4years, (B)CD4%at4years, (C)proportionof childrenwith
normal CD4% at 4 years, (D) proportion of children with viral failure within 4 years. Panels A, B, and C illustrate splines; panel D illustrates a cubic function.
ARTICLE
PEDIATRICS Volume 134, Number 4, October 2014 e1111
M.F. Courcoux, G. Vaudre, A. Dehée (L),
A .Schnuriger (L), N. Le Gueyades (P),
C. De Bortoli (P); CHU Hôtel Dieu, Nantes:
F Méchinaud, V Reliquet, J. Arias (L),
A. Rodallec (L), E. André (L), I. Falconi (P),
A. Le Pelletier (P); Hôpital de l’Archet II,
Nice, F. Monpoux, J. Cottalorda (L),
S. Mellul (L); Hôpital Jean Verdier,
Bondy: E. Lachassinne; Laboratoire
de virologie-Hôpital Necker Enfants
Malades, Paris: J. Galimand (L),
C. Rouzioux (L), M.L. Chaix (L), Z. Benabadji
(P), M. Pourrat (P); Hôpital Cochin
Port-Royal-Saint Vincent de Paul, Paris:
G. Firtion, D. Rivaux,M.Denon, N. Boudjoudi,
F. Nganzali, A. Krivine (L), J.F. Méritet (L),
G. Delommois (L), C. Norgeux (L), C. Guérin
(P); Hôpital Louis Mourier, Colombes:
C. Floch, L. Marty, H. Hichou (L),
V. Tournier (P); Hôpital Robert Debré,
Paris: A. Faye, I. Le Moal, M. Sellier (P),
L. Dehache (P); Laboratoire de virologie,
Hôpital Bichat Claude Bernard, Paris:
F. Damond (L), J. Leleu (L), D. Beniken
(L), G. Alexandre-Castor (L).
Germany: Universitäts-Kinderklinik
Düsseldorf: J. Neubert, T. Niehues,
H.J. Laws, K. Huck, S. Gudowius,
K. Siepermann, H. Loeffler, S. Bellert (L),
A. Ortwin (L); Universitäts-Kinderkliniken,
Munich: G. Notheis, U. Wintergerst,
F. Hoffman, A. Werthmann, S. Seyboldt,
L. Schneider, B. Bucholz; Charité-Medizische
Fakultät der Humboldt—Universitätzu
Berlin: C. Feiterna-Sperling, C. Peiser,
R. Nickel, T. Schmitz, T. Piening, C. Müller
(L); Kinder und Jugendklinik, Universität
Rostock: G. Warncke, M. Wigger,
R. Neubauer.
Ireland: Our Lady’s Children’s Hospital
Crumlin, Dublin: K. Butler, A.L. Chong,
T. Boulger, A. Menon, M. O’Connell,
L. Barrett, A. Rochford, M. Goode,
E. Hayes, S. McDonagh, A. Walsh, A. Doyle,
J. Fanning (P), M. O’Connor (P), M. Byrne
(L), N. O’Sullivan (L), E. Hyland (L).
Italy: Clinica Pediatrica, Ospedale
L. Sacco, Milan: V. Giacomet, A. Viganò,
I. Colombo, D. Trabattoni (L), A. Berzi (L);
Clinica Pediatrica, Università di Brescia:
R. Badolato, F. Schumacher, V. Bennato,
M. Brusati, A. Sorlini, E. Spinelli,
M. Filisetti, C. Bertulli; Clinica Pediatrica,
Università di Padova: O. Rampon,
C. Giaquinto, M. Zanchetta (L); Ospedale
S. Chiara, Trento: A. Mazza, G. Stringari,
G. Rossetti (L); Ospedale del Bambino
Gesù, Rome: S. Bernardi, A. Martino,
G. Castelli Gattinara, P. Palma, G. Pontrelli,
H. Tchidjou, A. Furcas, C. Frillici, A. Mazzei,
A. Zoccano (P), C. Concato (L).
Romania: Spitalul Clinic deBoli Infectioase
Victor Babes, Bucharest: D Duiculescu,
COprea, GTardei (L), FAbaab (P); Institutul
de Boli Infectioase Matei Bals, Bucharest:
M Mardarescu, R Draghicenoiu, D Otelea
(L), L Alecsandru (P); Clinic Municipal,
Constanta:RMatusa,SRugina,MIlie,Silvia
Netescu (P). Clinical monitors: C Florea,
TABLE 3 Projected Probabilities of Ever Recovering a Normal CD4% Within 4 Years, by WHO Immunodeficiency Classification and Agea,b
Baseline WHO Immune
Deficiency Classification
Age at HAART Initiation Overallc
n = 162
% (95% CI)0 to ,1 y
n = 26
% (95% CI)
1 to ,3 y
n = 19
% (95% CI)
3 to ,5 y
n = 24
% (95% CI)






13 to ,18 y
n = 17
% (95% CI)
Mild, n = 31 97 (88% to 100%) 96 (88% to 100%) 96 (87% to 100%) 95 (86% to 100%) 93 (82% to 100%) 91d (76% to 100%) 95 (86% to 100%)
Advanced, n = 40 95 (75% to 100%) 92 (74% to 100%) 86 (72% to 100%) 80 (68% to 92%) 70 (53% to 86%) 56 (27% to 85%) 80 (68% to 92%)
Severe, n = 91 83 (69% to 98%) 77 (65% to 90%) 69 (59% to 78%) 59 (50% to 68%) 44 (31% to 56%) 22 (0% to 44%) 59 (50% to 68%)
Overall,e n = 162 94 (83% to 100%) 88 (79% to 97%) 80 (73% to 86%) 70 (64% to 77%) 56 (46% to 65%) 35 (18% to 52%) 71 (65% to 77%)
a Additive Poisson regression estimates; adjusted for age, gender, race, and interaction between WHO Immunologic Classification and age; estimated at the covariate distribution of primary
outcome subset.
b Wald upper 95% confidence limits exceeding 100% were rounded to 100%.
c Overall WHO category estimates are at the primary endpoint subset mean age (6.3 y).
d n = 0 for this cell.
e Overall age estimates are adjusted for gender and race only.
TABLE 4 Projected Probabilities of Having a Normal CD4% at 4 Years, by WHO Immunodeficiency Classification and Agea,b
Baseline WHO Immune
Deficiency Classification
Age at HAART Initiationc Overallc
n = 182
% (95% CI)0 to ,1 y
n = 35
% (95% CI)
1 to ,3 y
n = 25
% (95% CI)
3 to ,5 y
n = 25
% (95% CI)
5 to ,8 y
n = 45
% (95% CI)
8 to ,13 y
n = 38
% (95% CI)
13 to ,18 y
n = 14
% (95% CI)
None, n = 37 99 (88% to 100%) 97 (87% to 100%) 93 (85% to 100%) 89 (80% to 98%) 83 (70% to 96%) 74 (53% to 96%) 90 (81% to 99%)
Mild, n = 27 86 (67% to 100%) 83 (65% to 100%) 80 (63% to 97%) 76 (59% to 93%) 70 (51% to 89%) 61d (36% to 86%) 77 (60% to 94%)
Advanced, n = 38 74 (55% to 94%) 72 (54% to 90%) 69 (52% to 85%) 65 (49% to 80%) 59 (42% to 75%) 50 (28% to 71%) 66 (50% to 81%)
Severe, n = 80 56 (41% to 70%) 53 (41% to 66%) 50 (39% to 61%) 46 (35% to 57%) 40 (27% to 53%) 31 (11% to 52%) 47 (36% to 58%)
Overall,e n = 182 75 (64% to 85%) 72 (63% to 81%) 68 (60% to 75%) 63 (56% to 70%) 56 (45% to 66%) 45 (27% to 63%) 64 (58% to 71%)
a Additive Poisson regression estimates; adjusted for age, gender, and race; estimated at covariate distribution of secondary outcomes subset.
b Wald upper 95% confidence limits exceeding 100% were rounded to 100%.
c Overall WHO category estimates are at the secondary end point subset mean age (5.8 y).
d n = 0 for this cell.
e Overall age estimates are adjusted for gender and race only.
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E Voicu, D Poalelungi, C Belmega, LVladau,
A Chiriac.
Spain: Hospital Materno-Infantil 12 de
Octubre, Madrid: J.T. Ramos Amador,
M.I. Gonzalez Tomé, P. Rojo Conejo,
M. Fernandez, R. Delgado Garcia (L),
J.M. Ferrari (P); Institute de Salud
Carlos III, Madrid: M. Garcia Lopez,
M.J. Mellado Peña, P. Martin Fontelos,
I. Jimenez Nacher (P); Biobanco Gregorio
Marañon, Madrid: M.A. Muñoz Fernandez
(L), J.L. Jimenez (L), A. García Torre (L);
clinical monitors: M. Penin, R. Pineiro
Perez, I. Garcia Mellado.
United Kingdom: Bristol Royal Chil-
dren’s Hospital: A. Finn, M. LaJeunesse,
E. Hutchison, J. Usher (L), L. Ball (P),
M. Dunn (P); St George’s Healthcare NHS
Trust, London: M. Sharland, K. Doerholt,
S. Storey, S. Donaghy, R. Chakraborty,
C. Wells (P), K. Buckberry (P), P. Rice (P);
University Hospital of North Staffordshire:
P. McMaster, P. Butler, C. Farmer (L),
J. Shenton (P), H. Haley (P), J. Orendi (L),
University Hospital Lewisham: J. Stroobant,
L. Navarante, P. Archer, C.Mazhude, D. Scott,
R. O’Connell, J. Wong (L), G. Boddy (P);
Sheffield Children’s Hospital: F. Shackley,
R. Lakshman, J. Hobbs, G. Ball (L),
G. Kudesia (L), J. Bane (P), D. Painter (P);
Ealing Hospital NHS Trust: K. Sloper,
V. Shah, A. Cheng (P), A. Aali (L); King’s
CollegeHospital, London: C. Ball, S. Hawkins,
D.Nayagam,A.Waters, S.Doshi (P);Newham
University Hospital: S. Liebeschuetz,
B. Sodiende, D. Shingadia, S. Wong,
J. Swan (P), Z. Shah (P); Royal Devon and
Exeter Hospital: A. Collinson, C. Hayes,
J. King (L), K. O’Connor (L); Imperial
College Healthcare NHS Trust, London:
G. Tudor-Williams, H. Lyall, K. Fidler,
S. Walters, C. Foster, D. Hamadache,
C. Newbould, C. Monrose, S. Campbell,
S. Yeung, J. Cohen, N. Martinez-Allier,
D. Melvin, J. Dodge, S. Welch, G. Tatum,
A. Gordon, S. Kaye (L), D. Muir (L), D. Patel
(P); Great OrmondStreet Hospital: V. Novelli,
D. Gibb, D. Shingadia, K. Moshal, J. Lambert,
N. Klein, J. Flynn, L. Farrelly, M. Clapson,
L. Spencer, M. Depala (P); Institute of Child
Health, London: M. Jacobsen (L); John
Radcliffe Hospital, Oxford: S. Segal,
A. Pollard, D. Kelly, S. Yeadon, B. Ohene-Kena
Y. Peng (L), T. Dong (L), Y. Peng (L), K. Jeffries
(L), M. Snelling (P), Nottingham University
Hospitals: A. Smyth, J. Smith; Chelsea and
Westminster Hospital, London: B. Ward;
Mortimer Market Centre, London:
E. Jungmann; Doncaster Royal Infirmary:
C. Ryan, K. Swaby; HealthProtectionAgency,
London: A. Buckton (L); Health Protection
Agency, Birmingham: E. Smit (L).
United States: Harlem Hospital Center:
E.J. Abrams, S. Champion, A.D. Fernandez,
D. Calo, L. Garrovillo, K. Swaminathan,
T. Alford, M. Frere, Columbia University
Laboratories, J. Navarra (P, Town Total
Health); New York University School of
Medicine: W. Borkowsky, S. Deygoo,
T. Hastings, S. Akleh, T. Ilmet (L); Seattle
Children’s Hospital: A. Melvin, K. Mohan,
G. Bowen (additional support by National
Institutes of Health grant UL1 RR025014);
University of South Florida: P.J. Emmanuel,
J. Lujan-Zimmerman, C. Rodriguez,
S. Johnson, A. Marion, C. Graisbery,
D. Casey, G. Lewis; All Children’s Hos-
pital Laboratories; Oregon Health and
Science University: J. Guzman-Cottrill,
R. Croteau; San Juan City Hospital:
M. Acevedo-Flores, M. Gonzalez, L. Angeli;
L. Fabregas, Laboratory 053, P Valentin
(P); State University of New York
(SUNY) Upstate Medical University,
Syracuse: L. Weiner, K.A. Contello,
W. Holz, M. Butler; SUNY, Health Science
Center at Stonybrook: S. Nachman,
M.A. Kelly, D.M. Ferraro, University of
North Carolina Retrovirology Labora-
tory; Howard University Hospital:
S. Rana, C. Reed, E. Yeagley, A. Malheiro,
J. Roa; Los Angeles County and Univer-
sity of Southern California Medical
Center: M. Neely, A. Kovacs, L. Spencer,
J. Homans, Y. Rodriguez Lozano, Mater-
nal Child Virology Research Laboratory,
Investigational Drug Service; South
Florida Children’s Diagnostic & Treat-
ment Center: A. Puga, G. Talero, R. Sellers;
Broward General Medical Center, Uni-
versity of Miami (L); University College of
Florida College of Medicine—Gainesville:
R. Lawrence; University of Rochester Pe-
diatrics: G.A. Weinberg, B. Murante,
S. Laverty; Miller Children’s Hospital
Long Beach: A. Deveikis, J. Batra, T. Chen,
D. Michalik, J. Deville, K. Elkins, S. Marks,
J. Jackson Alvarez, J. Palm, I. Fineanganofo
(L), M. Keuth (L), L. Deveikis (L),
W. Tomosada (P); Tulane University
New Orleans: R. Van Dyke, T. Alchediak,
M. Silio, C. Borne, S. Bradford, S. Eloby-
Childress (L), K. Nguyen (P); University
of Florida/Jacksonville: M.H. Rathore,
A. Alvarez; A. Mirza, S. Mahmoudi,
M. Burke; University of Puerto Rico:
I.L. Febo, L. Lugo, R. Santos; Children’s
Hospital Los Angeles: J.A. Church,
T. Dunaway, C. Rodier; St Jude/University
of Tennessee Health Science Center:
P. Flynn, N. Patel, S. DiScenza, M. Donohoe;
Western New England Maternal Pediatric
Adolescent AIDS: K. Luzuriaga, D. Picard;
Texas Children’s Hospital: M. Kline,
M.E. Paul, W.T. Shearer, C. McMullen-
Jackson; Children’s Memorial Hos-
pital, Chicago: R. Yogev, E. Chadwick,
E. Cagwin, K. Kabat; New Jersey Medical
School: A. Dieudonne, P. Palumbo,
J. Johnson; Robert Wood Johnson Medi-
cal School, New Brunswick: S. Gaur,
L. Cerracchio; Columbia IMPAACT: M. Foca,
A. Jurgrau, S. Vasquez Bonilla, G. Silva;
Babies’ Hospital, Columbia/Presbyterian
Medical Center, New York: A. Gershon;
University of Massachusetts Medical
Center, Worcester: J. Sullivan; University
of California—Los Angeles Medical
Center: Y. Bryson; Children’s Hospital,
Seattle: L. Frenkel; University of North
Carolina—Chapel Hill Virology Labora-
tory: S. Fiscus (L), J. Nelson (L).
Trials Units/Support
INSERM SC10 Paris: J.P. Aboulker,
A. Compagnucci, G. Hadjou, S. Léonardo,
Y. Riault, Y. Saïdi.
Medical ResearchCouncil Clinical Trials
Unit,UnitedKingdom:A.Babiker, L.Buck,
J.H. Darbyshire, L. Farrelly, S. Forcat,
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D.M.Gibb, H. Castro, L. Harper, L. Harrison,
J. Horton, D. Johnson, S.Moore, C. Taylor,
A.S. Walker.
Westat/NICHD: D. Collins, S. Buskirk,
P. Kamara, C. Nesel, M. Johnson,
A. Ferreira.
Frontier Science: J. Hodge, J. Tutko,
H. Sprenger.
IMPAACT: M. Hughes, M. Warshaw,
P. Britto, C. Powell.
National Institute of Allergy and In-
fectious Diseases: R. DerSimonian,
E. Handelsman (deceased).
PENTA Steering Committee: J.P. Aboulker,
J. Ananworanich, A. Babiker, E. Belfrage,
S. Bernardi, S. Blanche, A.B. Bohlin,
R. Bologna, D. Burger, K. Butler,
G. Castelli-Gattinara, H. Castro, P. Clayden,
A. Compagnucci, J.H. Darbyshire,
M. Debré, R. De Groot, M. Della Negra,
A. De Rossi, A. Di Biagio, D. Duiculescu,
A. Faye, V. Giacomet, C. Giaquinto
(Chair), D.M. Gibb, I. Grosch-Wörner,
M. Hainault, L. Harper, N. Klein,M. Lallemant,
J. Levy, H. Lyall, M. Marczynska,
M. Mardarescu, M.J. Mellado Pena,
D. Nadal, L. Naver, T. Niehues, C. Peckham,
D. Pillay, J. Popieska, J.T. Ramos Amador,
L. Rosado, R. Rosso (deceased), C. Rudin,
Y. Saïdi, H. Scherpbier, M. Sharland,
M. Stevanovic, C. Thorne, P.A. Tovo,
G. Tudor-Williams, A.S. Walker, S. Welch,
U. Wintergerst, N. Valerius.
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Methodological advice was provided by
C. Poole and S.R. Cole, University of
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